Britain and America have secured a major trade agreement that will ensure zero duties on UK drug shipments entering the American market.
The Terms of the Pact
Under the terms of the agreement, the UK has committed to increase spending on pharmaceuticals through the National Health Service (NHS). This pledge guarantees that import taxes on these crucial goods will stay at nothing for a duration of three years.
This deal is in response to earlier statements to hike duties on patented pharmaceutical imports, with increases floated up to double the cost.
"This arrangement between the United Kingdom bolsters the global environment for innovative medicines and introduces much-needed equity to U.S.–U.K. drug exports," a release declared.
Trade Significance
Drugs constitute one of the UK's largest exports to the America, which is clearly the biggest market for major companies like GSK and AstraZeneca.
Export figures indicate that in the 12 months leading up to last September, the UK shipped drugs valued at billions to the US. This value accounted for a significant portion of total UK exports in that period.
"This agreement secures work, boosts funding and paves the way for the UK to emerge as a global hub for biotech and pharma," a government official stated.
Key UK Commitments
The pact entails several specific pledges from the UK:
- Revised Affordability Limit: The UK will lift the cost ceiling at which it judges new therapies to be prohibitively costly by 25%.
- Boosted Medicine Funding: There is a goal to raise overall NHS spending on treatments from 0.3% of GDP to 0.6 percent over the next decade.
- Rebate Cap: The amount manufacturers must refund to the NHS to stay within budget will be limited at 15%. Last year, refunds topped 20%.
Industry Background
The pact comes amid a protracted tension between the pharmaceutical industry and the UK government over medicine costs and approval rates.
This friction were exacerbated by arguments that US patients were charged a premium for the identical medicines than people in the other developed nations.
Recently, several significant drug company projects in the UK have been paused or abandoned, while multi-billion-dollar expansions have been pledged toward projects in the United States.
A senior figure publicly accepted that the NHS must spend more on medicines, noting that its spending on drugs had declined as a proportion of its resources over the last ten years.
